旭輝控股(00884.HK)全年核心虧損最少51億人民幣 解決方案取得重大進展
旭輝控股集團(00884.HK)發盈警,與2021年度利潤123.27億人民幣相比,預計2022年度錄得虧損介乎130-140億人民幣;全年核心虧損預計介乎51-56億人民幣。主要受中國房地產行業整體經營情況不佳以及疫情影響;交付下跌,令銷售物業已確認收入和溢利減少;對物業項目計提減值撥備增加;人民幣兌美元貶值產生匯兌虧損;及投資物業公值虧損。
此外,公司爲境外流動資金狀況制定全面解決方案取得重大進展,已就潛在全面解決方案與協調委員會展開討論,並預計最遲於3月31日與債券持有人小組展開討論。目前,並無任何債權人開展針對公司的法律程序。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.